Literature DB >> 7880809

Structures of aromatic inhibitors of influenza virus neuraminidase.

M J Jedrzejas1, S Singh, W J Brouillette, W G Laver, G M Air, M Luo.   

Abstract

Neuraminidase (NA), a surface glycoprotein of influenza virus, is a potential target for design of antiinfluenza agents. The crystal structure of influenza virus neuraminidase showed that in the active site 11 residues are universally conserved among all strains known so far. Several potent inhibitors based on the carbohydrate compound 2-deoxy-2,3-didehydro-D-N-acetylneuraminic acid (DANA) have been shown to bind to the conserved active site and to reduce virus infection in animals when administered by nasal spray. Inhibitors of this type are, however, rapidly excreted from physiological systems and may not be effective in order to provide long-time protection. A new class of specific NA inhibitors, which are benzoic acid derivatives, has been designed on the basis of the three-dimensional structure of the NA-DANA complex and modeling of derivatives of 4-(acetylamino)benzoic acid in the NA active site. Intermediates were synthesized and were shown to moderately inhibit the NA activity and to bind to the NA active site as predicted. These rudimentary inhibitors, 4-(acetylamino)-3-hydroxy-5-nitrobenzoic acid, 4-(acetylamino)-3-hydroxy-5-aminobenzoic acid, and 4-(acetylamino)-3-aminobenzoic acid, and their X-ray structures in complexes with N2 (A/Tokyo/3/67) and B/Lee/40 neuraminidases have been analyzed. The coordinates of such inhibitors complexed with NA were used as the starting model for further design of more potent benzoic acid inhibitors. Because the active site residues of NA are invariant, the designed aromatic inhibitors have the potential to become an antiviral drug against all strains of influenza virus.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7880809     DOI: 10.1021/bi00010a003

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  21 in total

1.  Analysis of inhibitor binding in influenza virus neuraminidase.

Authors:  B J Smith; P M Colman; M Von Itzstein; B Danylec; J N Varghese
Journal:  Protein Sci       Date:  2001-04       Impact factor: 6.725

2.  Development and testing of a de novo drug-design algorithm.

Authors:  Eric Pellegrini; Martin J Field
Journal:  J Comput Aided Mol Des       Date:  2003-10       Impact factor: 3.686

3.  Epitope analysis for influenza vaccine design.

Authors:  Enrique T Muñoz; Michael W Deem
Journal:  Vaccine       Date:  2005-01-19       Impact factor: 3.641

4.  Mutation effects of neuraminidases and their docking with ligands: a molecular dynamics and free energy calculation study.

Authors:  Zhiwei Yang; Gang Yang; Lijun Zhou
Journal:  J Comput Aided Mol Des       Date:  2013-11-12       Impact factor: 3.686

5.  Implications of protein conformations to modifying novel inhibitor Oseltamivir for 2009 H1N1 influenza A virus by simulation and docking studies.

Authors:  Sudha Singh; Anvita Gupta Malhotra; Mohit Jha; Khushhali Menaria Pandey
Journal:  Virusdisease       Date:  2018-09-01

Review 6.  Pneumococcal virulence factors: structure and function.

Authors:  M J Jedrzejas
Journal:  Microbiol Mol Biol Rev       Date:  2001-06       Impact factor: 11.056

7.  Pyrrolidinobenzoic acid inhibitors of influenza virus neuraminidase: the hydrophobic side chain influences type A subtype selectivity.

Authors:  Yanwu Li; Arundutt Silamkoti; Gundurao Kolavi; Liyuan Mou; Shelly Gulati; Gillian M Air; Wayne J Brouillette
Journal:  Bioorg Med Chem       Date:  2012-05-17       Impact factor: 3.641

8.  Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071.

Authors:  C Y Tai; P A Escarpe; R W Sidwell; M A Williams; W Lew; H Wu; C U Kim; D B Mendel
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

9.  Combining crystallographic information and an aspherical-atom data bank in the evaluation of the electrostatic interaction energy in an enzyme-substrate complex: influenza neuraminidase inhibition.

Authors:  Paulina M Dominiak; Anatoliy Volkov; Adam P Dominiak; Katarzyna N Jarzembska; Philip Coppens
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2009-04-18

10.  Sensitivity of molecular docking to induced fit effects in influenza virus neuraminidase.

Authors:  Louise Birch; Christopher W Murray; Michael J Hartshorn; Ian J Tickle; Marcel L Verdonk
Journal:  J Comput Aided Mol Des       Date:  2002-12       Impact factor: 3.686

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.